Claria Medical designed its minimally invasive system for hysterectomies to minimize patient risk and procedure time. [Image courtesy of Claria Medical]
Hysterectomies are among the most common surgeries for women, but “many current approaches fall short,” the Mountain View, California-based company says at its website.
“High container breach rates risk hidden cancer spread or bowel injury,” the company said. “Significant abdominal incisions leave scars and cause unnecessary hospital readmissions [and] procedure times are highly variable.”
Claria Medical describes its new option as “an intelligent system designed for safe extraction of an enlarged uterus using a vaginal approach with no mini-laparotomy, minimizing patient risk, recovery and scarring.”
Watch on-demand: The 2026 MDO Min-Vasive Medtech webinar series
In 2023, Claria Medical secured a strategic investment from Organon in a deal that gave the publicly traded device developer the option to acquire Claria Medical. Caria also says it has won grants from the National Science Foundation and National Institute of Health to “develop products to improve hysterectomy, myomectomy and other surgical procedures.”
How the minimally invasive Claria system works
The Claria system is indicated for “contained cutting, coring and extraction of tissue during laparoscopic hysterectomy,” according to the FDA classification order. The device was accepted into the FDA’s Safer Technologies Program (STeP), which is designed to expedite review for devices that could improve the safety of treatment or diagnostics.
This illustration of the Claria Medical system for minimally invasive hysterectomies highlights the SafeStop feature. [Image courtesy of Claria Medical]
The FDA defined that kind of device as “a prescription device consisting of an integrated power morcellator and a containment method that are intended to contain, reduce and remove gynecologic tissue that is not suspected to contain malignancy during minimally invasive surgery.”
The Claria system consists of three components: a handpiece, a container and a console that allows for communication between the two.
The handpiece has integrated lighting and a rotating cutter with a 34 mm cutting blade.
The Claria system’s handpiece [Image courtesy of Claria]
To perform a hysterectomy with the system, the uterus is first detached from the body laparoscopically. Then the container is inserted through the vagina into the abdominal cavity and the uterus is placed into the container.
For a hysterectomy with Claria Medical’s system, the uterus is laparoscopically deteched from the patient’s body and placed into the Claria system’s container inside the abdominal cavity. [Image courtesy of Claria Medical]
After the uterus is placed in the container, its rim is pulled outside of the patient for tissue reduction and removal using the handpiece, through which a tenaculum can grasp the tissue. To prevent organ damage or tissue spread, the handpiece’s blade automatically stops cutting if it contacts the container. [Image courtesy of Claria Medical]
There is also a contraindication for the removal of uterine tissue containing suspected fibroids in patients who are post-menopausal, over the age of 50 or candidates for en bloc tissue removal through the vagina or via a mini-laparotomy incision. The FDA left room for this contraindication to be lifted if clinical data supports it.
When used in women with fibroids, the system is indicated for women who are premenopausal and under age 50.
The FDA also required the labeling to carry a boxed warning identifying the risk of unsuspected cancer, the potential for dissemination and that use of this device has not been clinically demonstrated to reduce that risk.
You can learn more about the system and watch a video depicting the procedure at Claria Medical’s website.
![The SNAP test detects concussions in 90 seconds [Photo courtesy of Oculogica]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2026/10/Oculogica-SNAP-268x170.jpg)
